-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] The purpose of the stock incentive plan launched by listed companies is mostly to attract and retain talents, and at the same time fully mobilize the enthusiasm of the company's employees, enhance cohesion, and ensure the realization of the company's development strategy and business goal.
On August 15, Zhaoyan New Drug released the 2022 A-share restricted stock incentive plan (draft.
The draft shows that the company intends to grant 1,400,600 restricted shares to the incentive objects, and the underlying types of shares involved are RMB A-share ordinary shares, accounting for about 262% of the company's total share capital of 530 million shares at the time of the announcement of the draft pla.
The total number of underlying stocks involved in the company's equity incentive plan during the entire validity period does not exceed 10% of the company's total share capital when the draft incentive plan is announce.
The number of shares and stock options granted to any one of the incentive objects in the company's equity incentive plan during the entire validity period of the company does not exceed 1% of the company's total share capital when the draft incentive plan is announce.
The total number of incentive objects granted by this incentive plan is 611, including company directors, senior managers and core technology (business) backbones who served in the company (including controlled subsidiaries) when the company announced this incentive pla.
The grant price for the planned grant of restricted shares is 387 yuan per shar.
According to the data, Zhaoyan New Drug is a CRO enterpris.
The company focuses on the safety evaluation and monitoring services of the whole life cycle of drug.
Among them, the preclinical research service of drugs is the company's core business, and the main contents include drug non-clinical safety evaluation services, drug Efficacy research services, animal pharmacokinetic research services and drug screenin.
The 2021 annual report shows that Zhaoyan New Drug achieved a total operating income of 517 billion yuan, a year-on-year increase of 497%; net profit attributable to shareholders of the parent company was 557 million yuan, a year-on-year increase of 796%; basic earnings per share was 51 yua.
The 2022 semi-annual performance forecast shows that the company expects a net profit of about 341 million yuan to 402 million yuan in the first half of the year, an increase of about 128% to 168% year-on-yea.
From the perspective of CXO (pharmaceutical outsourcing service) to which the company belongs, in the current pharmaceutical industry, the growth rate of CXO performance is highly certai.
CITIC Securities expects that global biopharmaceutical investment, financing, mergers and acquisitions will continue to be active, supporting the iterative increase in global biopharmaceutical R&D and outsourcing demand; it is optimistic about the mid- to long-term growth of the domestic CXO industry, especially global CXO companie.
According to the research report of Huaan Securities, the overall compound growth rate of China’s CXO industry from 2015 to 2019 was more than twice the global compound growth rate of 9.
It is expected that by 2024, China’s CXO market will reach 21 billion US dollars, with a compound growth rate of 25.
The industry pointed out that with the rapid development of the CXO industry, leading companies are actively expanding production, and talents will lay the foundation for the next stage of developmen.
In addition to the equity incentive plan launched by Zhaoyan New Drug, many companies have issued relevant announcements earlie.
For example, Proton shares disclosed an equity incentive plan in April, and the number of restricted shares to be granted to incentive objects is 14 million share.
The initial grant price of restricted shares in the incentive plan is 45 yuan per shar.
Performance assessment goals: Taking the net profit in 2020 as the base, the net profit growth rate in 2022 will be no less than 190%; taking the 2020 net profit as the base, the net profit growth rate in 2023 will be no less than 220%; taking the 2020 net profit as Base, the net profit growth rate in 2024 will not be lower than 260.
Minovar will issue an announcement at the end of 2021, agreeing to determine December 7, 2021 as the grant date, and grant a total of 7,000,000 rights to 302 senior executives and key personnel, accounting for about 68% of the company's total share capita.
The assessment target is based on the company's operating income and net profit in 202 The growth rate of operating income from 2022 to 2024 is not less than 5%, 15% and 25% respectively; the growth rate of net profit after deduction is not less than 45.
, 60% and 100.
Recently, Minovar also released its shareholder return plan for the next three years (2022-2024.
The company stated that it can distribute dividends in cash, stock or a combination of cash and stoc.
The profit distribution method of cash dividends is preferre.
Under the condition that the profit distribution conditions are met, the company shall make annual profit distribution; under the conditional conditions, the company can make interim profit distributio.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyon.
On August 15, Zhaoyan New Drug released the 2022 A-share restricted stock incentive plan (draft.
The draft shows that the company intends to grant 1,400,600 restricted shares to the incentive objects, and the underlying types of shares involved are RMB A-share ordinary shares, accounting for about 262% of the company's total share capital of 530 million shares at the time of the announcement of the draft pla.
The total number of underlying stocks involved in the company's equity incentive plan during the entire validity period does not exceed 10% of the company's total share capital when the draft incentive plan is announce.
The number of shares and stock options granted to any one of the incentive objects in the company's equity incentive plan during the entire validity period of the company does not exceed 1% of the company's total share capital when the draft incentive plan is announce.
The total number of incentive objects granted by this incentive plan is 611, including company directors, senior managers and core technology (business) backbones who served in the company (including controlled subsidiaries) when the company announced this incentive pla.
The grant price for the planned grant of restricted shares is 387 yuan per shar.
According to the data, Zhaoyan New Drug is a CRO enterpris.
The company focuses on the safety evaluation and monitoring services of the whole life cycle of drug.
Among them, the preclinical research service of drugs is the company's core business, and the main contents include drug non-clinical safety evaluation services, drug Efficacy research services, animal pharmacokinetic research services and drug screenin.
The 2021 annual report shows that Zhaoyan New Drug achieved a total operating income of 517 billion yuan, a year-on-year increase of 497%; net profit attributable to shareholders of the parent company was 557 million yuan, a year-on-year increase of 796%; basic earnings per share was 51 yua.
The 2022 semi-annual performance forecast shows that the company expects a net profit of about 341 million yuan to 402 million yuan in the first half of the year, an increase of about 128% to 168% year-on-yea.
From the perspective of CXO (pharmaceutical outsourcing service) to which the company belongs, in the current pharmaceutical industry, the growth rate of CXO performance is highly certai.
CITIC Securities expects that global biopharmaceutical investment, financing, mergers and acquisitions will continue to be active, supporting the iterative increase in global biopharmaceutical R&D and outsourcing demand; it is optimistic about the mid- to long-term growth of the domestic CXO industry, especially global CXO companie.
According to the research report of Huaan Securities, the overall compound growth rate of China’s CXO industry from 2015 to 2019 was more than twice the global compound growth rate of 9.
It is expected that by 2024, China’s CXO market will reach 21 billion US dollars, with a compound growth rate of 25.
The industry pointed out that with the rapid development of the CXO industry, leading companies are actively expanding production, and talents will lay the foundation for the next stage of developmen.
In addition to the equity incentive plan launched by Zhaoyan New Drug, many companies have issued relevant announcements earlie.
For example, Proton shares disclosed an equity incentive plan in April, and the number of restricted shares to be granted to incentive objects is 14 million share.
The initial grant price of restricted shares in the incentive plan is 45 yuan per shar.
Performance assessment goals: Taking the net profit in 2020 as the base, the net profit growth rate in 2022 will be no less than 190%; taking the 2020 net profit as the base, the net profit growth rate in 2023 will be no less than 220%; taking the 2020 net profit as Base, the net profit growth rate in 2024 will not be lower than 260.
Minovar will issue an announcement at the end of 2021, agreeing to determine December 7, 2021 as the grant date, and grant a total of 7,000,000 rights to 302 senior executives and key personnel, accounting for about 68% of the company's total share capita.
The assessment target is based on the company's operating income and net profit in 202 The growth rate of operating income from 2022 to 2024 is not less than 5%, 15% and 25% respectively; the growth rate of net profit after deduction is not less than 45.
, 60% and 100.
Recently, Minovar also released its shareholder return plan for the next three years (2022-2024.
The company stated that it can distribute dividends in cash, stock or a combination of cash and stoc.
The profit distribution method of cash dividends is preferre.
Under the condition that the profit distribution conditions are met, the company shall make annual profit distribution; under the conditional conditions, the company can make interim profit distributio.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyon.
